IMO, I do not think "..under the radar .." meant that we were literally avoiding Big Pharma, it just meant that we are not ready to discuss and present our case to Big Phama yet. Plus as you are aware that late last year, another amazing discovery of Cardio-protection that needs more serious planning trials to prove further and its valuation could be as big as the potential of FTO. Covid has made things worse, our emd aml trial as been delay at least 4 months, I could imagine without this delay We could already have some data in HUMAN by now or soon.
So infact that even right now what do we have ? if we are facing Big Pharma apart from some good results of preclinical and historical data. I would imagine Big pharma would say ".... I am interested BUT I need more data pls.."IMO, it is all about timing, just like everything else in life, in order to have a max impact we must time it right and know when to make the right move.
I support wholeheartedly if RAC is not ready to have serious discussion with Big Pharma until we have modern HUMAN data emerging hopefully sometime this year 2022. Beside Big pharma is also a lot smarter then the average investors like us, they find us and snap RAC up in a heartbeat IF we are worth it. Anyway we are already and actively engaging with Big Pharma. (second biggest pharma in japan providing their drug for our trial).
To be fair, in saying that " we will not be where we are now this is managements fault.." is a bit too harsh and lack of a fair judgement.
RAC management deserves a better recognition for acting in the best interests of ALL share holders.
For the record, I am currently holding a few hundred thousands shares and have been accumulating since 8c and me too I am not concerned even a little bit the way that RAC heading to.
RAC Price at posting:
$2.57 Sentiment: Buy Disclosure: Held
(20min delay)